Rhythm CEO Kei­th Gottes­di­ener hits the ex­it; Take­da sets up an AI dis­cov­ery pro­gram at MIT

Rhythm Phar­ma­ceu­ti­cals $RYTM CEO Kei­th Gottes­di­ener is plan­ning to stay at the helm un­til the biotech com­pletes its new drug ap­pli­ca­tion, and then head out. He says it’s the right time to hand over the reins and the com­pa­ny plans to or­ga­nize a search for his re­place­ment. His last task should be done by the end of Q1. “For the more than eight years that I have been CEO, it has been an hon­or to lead the tal­ent­ed Rhythm team, and I am im­mense­ly proud of our work to ad­vance set­melan­otide and bol­ster the un­der­stand­ing of rare ge­net­ic dis­or­ders of obe­si­ty,” said Gottes­di­ener in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.